Branded generics sales will expand through 2036, with oral formulations at 65.0% of formulation type demand in 2026. The market was valued at USD 382.4 billion in 2025 and is projected to reach USD 928.6 billion by 2036, creating an incremental opportunity of USD 514.1 billion between 2026 and 2036.